This pharmaceutical company was conducting Phase 3 clinical trials for a drug that would offer a new type of pharma treatment for a high-prevalence condition. The client needed to gain a robust understanding of the existing patient flow and treatment dynamics in order to size the market opportunity in critical market segments. The brand team analyzed various data collection methodologies for robustness and the ability to provide required information and found:
The brand team concluded that a patient chart audit that was properly integrated with existing primary and secondary data would be the best choice for capturing an accurate snapshot of the current market and to help build a robust forecast model. Clarity Pharma was selected to provide this vital research. A nationally representative sample of target physicians extracted detailed information from the records of physicians’ last 4 patients whom they had seen with the target condition. The study met all 9 of our sample validity standards, ensuring it was representative and could be generalized.
The study provided:
The client gained actionable insight to its value and the core issues that needed to be addressed. For example, the company made a major change in the focus of its final Phase 3 clinical trials as a result of new insights gained from the Clarity study. The modifications were accepted by the FDA. The client also immediately began planning a course of action and implementing recommendations.